Tumour area infiltration and cell count in endoscopic biopsies of therapy-naive upper GI tract carcinomas by QuPath analysis: implications for predictive biomarker testing.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 10 2023
16 10 2023
Historique:
received:
25
09
2022
accepted:
29
09
2023
medline:
23
10
2023
pubmed:
17
10
2023
entrez:
16
10
2023
Statut:
epublish
Résumé
Guidelines regulate how many (tumour-bearing) tissue particles should be sampled during gastric cancer biopsy to obtain representative results in predictive biomarker testing. Little is known about how well these guidelines are applied, how the number of tissue particles correlates with the actual tumour-infiltrated area and how many absolute tumour cells are captured. The study included endoscopic biopsies of untreated carcinomas of the upper gastrointestinal (GI)-tract during the 2016-2020 review period. Archival (H&E)-stained histological sections were digitised and the tumour areas were manually annotated. The tumour-bearing tissue area and absolute carcinoma cell count per case were determined by image analysis and compared with a reference primary surgical specimen. Biopsies from 253 patients were analysed. The following mean values were determined: (a) tumour tissue particle number: 6.5 (range: 1-25, standard deviation (SD) = 3.33), (b) number of tumour-bearing tissue particles: 4.7 (range: 1-20, SD = 2.80), (c) tumour-infiltrated area: 7.5 mm
Identifiants
pubmed: 37845307
doi: 10.1038/s41598-023-43903-3
pii: 10.1038/s41598-023-43903-3
pmc: PMC10579338
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17580Informations de copyright
© 2023. Springer Nature Limited.
Références
Van Cutsem, E. et al. HER2 screening data from ToGA: Targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18, 476–484. https://doi.org/10.1007/s10120-014-0402-y (2015).
doi: 10.1007/s10120-014-0402-y
pubmed: 25038874
Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 398, 27–40. https://doi.org/10.1016/s0140-6736(21)00797-2 (2021).
doi: 10.1016/s0140-6736(21)00797-2
pubmed: 34102137
pmcid: 8436782
Sahin, U. et al. A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur. J. Cancer 100, 17–26. https://doi.org/10.1016/j.ejca.2018.05.007 (2018).
doi: 10.1016/j.ejca.2018.05.007
pubmed: 29936063
Catenacci, D. V. et al. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 15, 2073–2082. https://doi.org/10.2217/fon-2019-0141 (2019).
doi: 10.2217/fon-2019-0141
pubmed: 31094225
Jung, K. W. et al. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2014. Cancer Res. Treat. 49, 292–305. https://doi.org/10.4143/crt.2017.118 (2017).
doi: 10.4143/crt.2017.118
pubmed: 28279062
pmcid: 5398380
Lepage, C., Rachet, B., Jooste, V., Faivre, J. & Coleman, M. P. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am. J. Gastroenterol. 103, 2694–2699. https://doi.org/10.1111/j.1572-0241.2008.02191.x (2008).
doi: 10.1111/j.1572-0241.2008.02191.x
pubmed: 18853967
Kamangar, F. et al. The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5, 582–597. https://doi.org/10.1016/s2468-1253(20)30007-8 (2020).
doi: 10.1016/s2468-1253(20)30007-8
Grabsch, H., Sivakumar, S., Gray, S., Gabbert, H. E. & Müller, W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value—Conclusions from 924 cases of two independent series. Cell Oncol. 32, 57–65. https://doi.org/10.3233/clo-2009-0497 (2010).
doi: 10.3233/clo-2009-0497
pubmed: 20208134
pmcid: 4619246
Ye, P. et al. Intra-tumoral heterogeneity of HER2, FGFR2, cMET and ATM in gastric cancer: Optimizing personalized healthcare through innovative pathological and statistical analysis. PLoS ONE 10, e0143207. https://doi.org/10.1371/journal.pone.0143207 (2015).
doi: 10.1371/journal.pone.0143207
pubmed: 26587992
pmcid: 4654477
Schoemig-Markiefka, B. et al. Optimized PD-L1 scoring of gastric cancer. Gastric Cancer 24, 1115–1122. https://doi.org/10.1007/s10120-021-01195-4 (2021).
doi: 10.1007/s10120-021-01195-4
pubmed: 33954872
pmcid: 8338825
Lordick, F. et al. HER2 testing in gastric cancer: Results of a German expert meeting. J. Cancer Res. Clin. Oncol. 143, 835–841. https://doi.org/10.1007/s00432-017-2374-x (2017).
doi: 10.1007/s00432-017-2374-x
pubmed: 28285403
pmcid: 5384945
Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376, 687–697. https://doi.org/10.1016/s0140-6736(10)61121-x (2010).
doi: 10.1016/s0140-6736(10)61121-x
pubmed: 20728210
Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7, 16878. https://doi.org/10.1038/s41598-017-17204-5 (2017).
doi: 10.1038/s41598-017-17204-5
pubmed: 29203879
pmcid: 5715110
Schmidt, U. et al. Cell detection with star-convex polygons. In International Conference on Medical Image Computing and Computer-Assisted Intervention (MICCAI), Granada, Spain (2018).
Rubin, I. & Yarden, Y. The basic biology of HER2. Ann. Oncol. 12(Suppl 1), S3-8. https://doi.org/10.1093/annonc/12.suppl_1.s3 (2001).
doi: 10.1093/annonc/12.suppl_1.s3
pubmed: 11521719
Ménard, S., Pupa, S. M., Campiglio, M. & Tagliabue, E. Biologic and therapeutic role of HER2 in cancer. Oncogene 22, 6570–6578. https://doi.org/10.1038/sj.onc.1206779 (2003).
doi: 10.1038/sj.onc.1206779
pubmed: 14528282
Ruschoff, J. et al. HER2 testing in gastric cancer: A practical approach. Mod. Pathol. 25, 637–650. https://doi.org/10.1038/modpathol.2011.198 (2012).
doi: 10.1038/modpathol.2011.198
pubmed: 22222640